The British Journal of Rheumatology, Vol 36, 255-259, Copyright © 1997 by British Society for Rheumatology
JD Adachi, WG Bensen, MJ Bell, FA Bianchi, AA Cividino, GL Craig, WC Sturtridge, RJ Sebaldt, M Steele, M Gordon, E Themeles, P Tugwell, R Roberts and M Gent
The objectives were to determine the efficacy and safety of nasal salmon
calcitonin 200 IU daily in the prevention of corticosteroid- induced
osteoporosis. A minimized, double-blind, placebo-controlled trial was
carried out in corticosteroid-treated patients with polymyalgia rheumatica.
The setting was a tertiary care university- affiliated hospital and a total
of 31 patients were enrolled. The primary outcome measure was the
percentage change in bone mineral density of the lumbar spine in the two
treatment groups from baseline to 1 yr of follow-up. The mean +/- S.D. bone
mineral density of the lumbar spine in the calcitonin-treated group
decreased by 1.29 +/- 6.76% and in the placebo group by 4.95 +/- 3.50%
after 12 months. The observed difference of 3.65 +/- 2.10% between groups
is statistically significant (P < 0.05). Nasal salmon calcitonin
prevented loss of bone in the lumbar spine as measured by dual-energy X-ray
absorptiometry.
ORIGINAL PAPERS
Salmon calcitonin nasal spray in the prevention of corticosteroid- induced osteoporosis
St Joseph's Hospital, McMaster University, Hamilton, Ontario, Canada.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H Tilg, A R Moschen, A Kaser, A Pines, and I Dotan Gut, inflammation and osteoporosis: basic and clinical concepts Gut, May 1, 2008; 57(5): 684 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Adler and M. C. Hochberg Suggested Guidelines for Evaluation and Treatment of Glucocorticoid-Induced Osteoporosis for the Department of Veterans Affairs Arch Intern Med, November 24, 2003; 163(21): 2619 - 2624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Brown and R. G. Josse Lignes directrices de pratique clinique 2002 pour le diagnostic et le traitement de l'osteoporose au Canada Can. Med. Assoc. J., March 18, 2003; 168(90060): SF1 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Brown and R. G. Josse 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada Can. Med. Assoc. J., November 12, 2002; 167(90100): s1 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Yeap and D. J. Hosking Management of corticosteroid-induced osteoporosis Rheumatology, October 1, 2002; 41(10): 1088 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Yood, L. R. Harrold, L. Fish, J. Cernieux, S. Emani, E. Conboy, and J. H. Gurwitz Prevention of Glucocorticoid-Induced Osteoporosis: Experience in a Managed Care Setting Arch Intern Med, May 28, 2001; 161(10): 1322 - 1327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Yosipovitch, T. S. Hoon, and G. C. Leok Suggested Rationale for Prevention and Treatment of Glucocorticoid-Induced Bone Loss in Dermatologic Patients Arch Dermatol, April 1, 2001; 137(4): 477 - 481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. R. Reid Time to End Steroid-Induced Fractures Arch Dermatol, April 1, 2001; 137(4): 493 - 494. [Full Text] [PDF]
|
|
|
|
 |
|
 I. R. Reid Glucocorticoid Osteoporosis: Reid IR Glucocorticoid osteoporosis J Intensive Care Med 1999, 14231-242 J Intensive Care Med, September 1, 1999; 14(5): 231 - 242. [PDF]
|
|